COMMUNIQUÉS West-GlobeNewswire

Eleusis to Debut as the World’s First Legal Luxury Psychedelic Immersion
03/02/2026
ST VINCENT AND THE GRENADINES, Caribbean, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Eleusis , the world’s first legal luxury psychedelic immersion, using DMTx protocols, will officially debut in March 2026 on the island of [...]
Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA
03/02/2026
Access the “What This Means” segment here CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced [...]
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
03/02/2026
RICHMOND, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 35,190,292 shares of its [...]
SRx Health Solutions Significantly Reduces Short Position of Cryptocurrency Portfolio Amidst Current Market Volatility
03/02/2026
NORTH PALM BEACH, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") today announced it has significantly reduced its short position across its cryptocurrency [...]
Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026
03/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its [...]
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3
03/02/2026
GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026 Phase 1 protocol allows multiple solid tumor types known to express B7-H3 Unaudited proforma cash balance as of January 31, 2026 of [...]
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
03/02/2026
Phase 1 study of PRT12396 in patients with polycythemia vera and myelofibrosis anticipated to initiate by Q2 2026 WILMINGTON, Del., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a [...]
HFMA’s Vitalic Health to gather more than 50 payers, providers and tech leaders to address rising claim denials
03/02/2026
CHICAGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- The Healthcare Financial Management Association’s Vitalic Health announced today it will convene more than 50 payers, providers and tech companies to simplify and standardize [...]
Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026
03/02/2026
- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in an invited session at the 41 st Asia-Pacific Academy of Ophthalmology (APAO [...]
Clever Care Health Plan Increases Enrollment by Nearly 50 Percent in 2026 Medicare Annual Enrollment Period
03/02/2026
Culturally competent Medicare Advantage plan also announces new grocery benefits at major retailers and community-centered grocery stores HUNTINGTON BEACH, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Clever Care Health [...]
Mark Mikhael, CEO of Olympia and Wesley Pharmaceuticals, Appointed to the Florida Board of Pharmacy by Governor Ron DeSantis
03/02/2026
Healthcare veteran and compounding advocate to bring over 20 years of clinical excellence to the state’s regulatory body ORLANDO, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Olympia and Wesley Pharmaceuticals, two of the [...]
Mapi Pharma to Present New Safety and Efficacy Data from Glatiramer Acetate Depot Long-Acting Injection Phase II Study in Patients with Primary Progressive Multiple Sclerosis (PPMS) at ACTRIMS Forum 2026
03/02/2026
NESS ZIONA, Israel, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable [...]
Cynet Named a Strong Performer in 2026 Gartner Peer Insights™ “Voice of the Customer” for Endpoint Protection Platforms
03/02/2026
Customers cite Cynet’s “reliable endpoint protection” and “unified security platform” with 95% willingness to recommend BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Cynet , the unified, AI-powered cybersecurity platform, [...]
MedRisk Acquires Horizon Casualty Services
03/02/2026
Strengthens MedRisk’s ability to deliver better outcomes and an elevated experience WEST CONSHOHOCKEN, Pa., Feb. 03, 2026 (GLOBE NEWSWIRE) -- MedRisk, a leading provider of managed care solutions for the workers’ [...]
Adam Ferrari Announces 2026 Health Science Scholarship to Support Students Dedicated to Caring for Patients with Physical Disabilities
03/02/2026
IRVINE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adam Ferrari, the Chief Executive Officer of Phoenix Energy, is pleased to announce the launch of the 2026 Adam Ferrari Health Science Scholarship, a $20,000 academic [...]
Department of Education Proposal Still Excludes Nursing from “Professional Degree” Definition
03/02/2026
ANA urges nurses, patients, and the public to submit comments demanding nursing be added SILVER SPRING, MD, Feb. 03, 2026 (GLOBE NEWSWIRE) -- The American Nurses Association (ANA) is deeply concerned that the U.S. [...]
AdhereHealth Announces Appointment of CEO Kempton Presley and President & COO Patrick McNulty as Members of the Board of Directors
03/02/2026
NASHVILLE, Tenn., Feb. 03, 2026 (GLOBE NEWSWIRE) -- AdhereHealth today announced the appointment of Kempton Presley, Chief Executive Officer, and Patrick “Pat” McNulty, President and Chief Operating Officer, as members [...]
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program
03/02/2026
Collaboration reinforces regulatory diligence, nonclinical strategy and clinical trial integrity for novel intranasal concussion therapy Traumatic brain injuries affect more Americans each year than stroke, Alzheimer’s [...]
Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch
03/02/2026
Oral presentation provides additional scientific rationale on Krabbe disease, one of four LSDs in the Phase 2 SOTERIA basket trial designed to evaluate the safety and clinical activity of lead drug candidate PLX-200 [...]

Pages